Genomic grade adds prognostic value in invasive lobular carcinoma.

Auteurs : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : Ann Oncol
Volume : 24
Pagina's : 377-384

Genomic grade adds prognostic value in invasive lobular carcinoma.

Auteurs : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : Ann Oncol
Volume : 24(2)
Pagina's : 377-84

CD4+ follicular helper T cell infiltration predicts breast cancer survival.

Auteurs : Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart-Gebhart M, Sotiriou C, Willard-Gallo K
Jaar : 2013
Journal : J Clin Invest
Volume : 123(7)
Pagina's : 2873-92

Sustained Viral Suppression and Higher CD4+ T-Cell Count Reduces the Risk of Persistent Cervical High-Risk Human Papillomavirus Infection in HIV-Positive Women.

Auteurs : Konopnicki D, Manigart Y, Gilles C, Barlow P, De Marchin J, Feoli F, Larsimont D, Delforge M, De Wit S, Clumeck N
Jaar : 2013
Journal : J. Infect. Dis.
Volume : 207(11)
Pagina's : 1723-9

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis.

Auteurs : Azim HA, Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart-Gebhart M, Michiels S, Sotiriou C
Jaar : 2013
Journal : PLoS One
Volume : 8(4)
Pagina's : e62451

Change in the microenvironment of breast cancer studied by FTIR imaging.

Auteurs : Kumar S, Desmedt C, Larsimont D, Sotiriou C, Goormaghtigh E
Jaar : 2013
Journal : Analyst
Volume : 138(14)
Pagina's : 4058-65

Breast cancer and melanoma cell line identification by FTIR imaging after formalin-fixation and paraffin-embedding.

Auteurs : Verdonck M, Wald N, Janssis J, Yan P, Meyer C, Legat A, Speiser DE, Desmedt C, Larsimont D, Sotiriou C, Goormaghtigh E
Jaar : 2013
Journal : Analyst
Volume : 138(14)
Pagina's : 4083-91

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients.

Auteurs : El Hajj P, Journe F, Wiedig M, Laios I, Sales F, Galibert MD, Van Kempen LC, Spatz A, Badran B, Larsimont D, Awada A, Ghanem G
Jaar : 2013
Journal : Br J Cancer
Volume : 108(8)
Pagina's : 1641-7

Metasin-An Intra-Operative RT-qPCR Assay to Detect Metastatic Breast Cancer in Sentinel Lymph Nodes.

Auteurs : Al-Ramadhani S, Sai-Giridhar P, George D, Gopinath P, Arkoumani E, Jader S, Sundaresan M, Salgado R, Larsimont D, Bustin SA, Sundaresan V
Jaar : 2013
Journal : Int J Mol Sci
Volume : 14(7)
Pagina's : 12931-52

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Auteurs : Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : PLoS One
Volume : 8(8)
Pagina's : e66848

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Auteurs : Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A
Jaar : 2013
Journal : Future Oncol
Volume : 9(10)
Pagina's : 1477-87

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

Auteurs : Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, de Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell orto P, Larsimont D, Steinberg I, Gelber Rd, Piccart-Gebhart M, Viale G, Di Leo A
Jaar : 2013
Journal : Ann Oncol
Volume : 24(5)
Pagina's : 1203-11

High-risk human papillomavirus infection in HIV-positive African women living in Europe.

Auteurs : Konopnicki D, Manigart Y, Gilles C, Barlow P, De Marchin J, Feoli F, Larsimont D, Delforge M, De Wit S, Clumeck N
Jaar : 2013
Journal : J Int AIDS Soc
Volume : 16
Pagina's : 18023

Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.

Auteurs : Goris Gbenou M, Peltier A, Addla SK, Lemort M, Bollens R, Larsimont D, Roumeguère T, Schulman CC, Van Velthoven R
Jaar : 2012
Journal : Urol. Int.
Volume : 88(1)
Pagina's : 12-7

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Auteurs : Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, de Azambuja E, Hainaut P, + collaborators (among others :, Larsimont D, Piccart-Gebhart M, Olivier M
Jaar : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pagina's : R70

Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment.

Auteurs : Desmedt C, Majjaj S, Kheddoumi N, Singhal SK, Haibe-Kains B, El Ouriaghli F, Chaboteaux C, Michiels S, Lallemand F, Journe F, Duvillier H, Loi S, Quackenbush J, Dekoninck S, Blanpain C, Lagneaux L, Houhou N, Delorenzi M, Larsimont D, Piccart-Gebhart M, Sotiriou C
Jaar : 2012
Journal : Clin Cancer Res
Volume : 18(4)
Pagina's : 1004-14

HER2-positive circulating tumor cells in breast cancer.

Auteurs : Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart-Gebhart M, Sotiriou C
Jaar : 2011
Journal : PLoS One
Volume : 6(1)
Pagina's : e15624

Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS).

Auteurs : Altintas S, Toussaint J, Durbecq V, Lambein K, Huizing MT, Larsimont D, Van Marck E, Vermorken JB, Tjalma WA, Sotiriou C
Jaar : 2011
Journal : Breast J
Volume : 17(4)
Pagina's : 343-51

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Auteurs : Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H
Jaar : 2011
Journal : Lancet Oncol
Volume : 12(12)
Pagina's : 1134-42

DNA methylation profiling reveals a predominant immune component in breast cancers.

Auteurs : Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothé F, Rouas G, Metzger O, Majjaj S, Saini K, Putmans P, Hames G, van Baren N, Coulie PG, Piccart-Gebhart M, Sotiriou C, Fuks F
Jaar : 2011
Journal : EMBO Mol Med
Volume : 3(12)
Pagina's : 726-41